1. Home
  2. CABA vs QBTS Comparison

CABA vs QBTS Comparison

Compare CABA & QBTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CABA
  • QBTS
  • Stock Information
  • Founded
  • CABA 2017
  • QBTS 1999
  • Country
  • CABA United States
  • QBTS Canada
  • Employees
  • CABA N/A
  • QBTS N/A
  • Industry
  • CABA Biotechnology: Biological Products (No Diagnostic Substances)
  • QBTS Retail: Computer Software & Peripheral Equipment
  • Sector
  • CABA Health Care
  • QBTS Technology
  • Exchange
  • CABA Nasdaq
  • QBTS Nasdaq
  • Market Cap
  • CABA 210.0M
  • QBTS 194.5M
  • IPO Year
  • CABA 2019
  • QBTS N/A
  • Fundamental
  • Price
  • CABA $2.45
  • QBTS $7.42
  • Analyst Decision
  • CABA Strong Buy
  • QBTS Strong Buy
  • Analyst Count
  • CABA 9
  • QBTS 6
  • Target Price
  • CABA $27.22
  • QBTS $5.63
  • AVG Volume (30 Days)
  • CABA 4.7M
  • QBTS 84.7M
  • Earning Date
  • CABA 11-14-2024
  • QBTS 11-14-2024
  • Dividend Yield
  • CABA N/A
  • QBTS N/A
  • EPS Growth
  • CABA N/A
  • QBTS N/A
  • EPS
  • CABA N/A
  • QBTS N/A
  • Revenue
  • CABA N/A
  • QBTS $9,424,000.00
  • Revenue This Year
  • CABA N/A
  • QBTS $4.82
  • Revenue Next Year
  • CABA N/A
  • QBTS $64.23
  • P/E Ratio
  • CABA N/A
  • QBTS N/A
  • Revenue Growth
  • CABA N/A
  • QBTS 14.27
  • 52 Week Low
  • CABA $1.76
  • QBTS $0.68
  • 52 Week High
  • CABA $26.35
  • QBTS $10.50
  • Technical
  • Relative Strength Index (RSI)
  • CABA 36.81
  • QBTS 62.66
  • Support Level
  • CABA $2.76
  • QBTS $3.71
  • Resistance Level
  • CABA $2.80
  • QBTS $10.50
  • Average True Range (ATR)
  • CABA 0.42
  • QBTS 1.48
  • MACD
  • CABA -0.05
  • QBTS 0.26
  • Stochastic Oscillator
  • CABA 4.26
  • QBTS 50.23

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.

About QBTS D-Wave Quantum Inc.

D-Wave Quantum Inc is engaged in the development and delivery of quantum computing systems, software, and services, and is the commercial supplier of quantum computers—and the only company building both annealing quantum computers and gate-model quantum computers. The Company's mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection, and financial modelling. D-Wave's annealing quantum computers are accessible through the Company's LeapTM cloud service.

Share on Social Networks: